Showing results (181-190 of 396) with videos related to
Sort By:
Pageof 40
Leukemia|May 20, 2005
Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5qC Schoch, A Kohlmann, M Dugas, et al.Leukemia|April 9, 2005
New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genesA Kohlmann, C Schoch, M Dugas, et al.Onkologie|February 1, 1988
High-dose cytosine arabinoside and mitoxantrone: preliminary results of a pilot study with sequential application (S-HAM) indicating a high antileukemic activity in refractory acute leukemiasW Hiddemann, T Büchner, M Essink, et al.Deutsche Medizinische Wochenschrift (1946)|October 1, 2014
[Metastatic colorectal cancer--analysis of treatment modalities and survival now and then]M Michl, B Holtzem, J Koch, et al.Seminars in Oncology|December 1, 1994
New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factorsW Hiddemann, B Wörmann, C Reuter, et al.British Journal of Haematology|May 22, 2008
Report of a workshop on malignant lymphoma: a review of molecular and clinical risk profilingB Gleissner, R Küppers, R Siebert, et al.Annals of Hematology|April 16, 1998
Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patientsG Behre, H Link, G Maschmeyer, et al.Cancer|July 15, 1982
Cell kinetics in acute leukemia: a critical reevaluation based on new dataW Hiddemann, T Büchner, M Andreeff, et al.Anti-Cancer Drugs|July 20, 2005
Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case reportH J Stemmler, O Weigert, M Krych, et al.Onkologie|February 1, 1987
High-dose cytosine arabinoside and mitoxantrone (HAM) for the treatment of refractory acute lymphoblastic leukemiaW Hiddemann, H Kreutzmann, R Donhuijsen-Ant, et al.Pageof 40